Global Information
회사소개 | 문의 | 위시리스트

세계의 혈우병 시장 분석 : 인사이트, 동향, 예측

Global Hemophilia Market Report: Insights, Trends and Forecast (2019-2023)

리서치사 Koncept Analytics
발행일 2019년 07월 상품 코드 879100
페이지 정보 영문 106 Pages
가격
US $ 1,700 ₩ 2,024,000 PDF by E-mail (Single User License)
US $ 2,300 ₩ 2,739,000 PDF by E-mail (Corporate User License)


세계의 혈우병 시장 분석 : 인사이트, 동향, 예측 Global Hemophilia Market Report: Insights, Trends and Forecast (2019-2023)
발행일 : 2019년 07월 페이지 정보 : 영문 106 Pages

세계의 혈우병(Hemophilia) 시장을 분석했으며, 질환의 개요 및 주요 진단·치료법, 세계 전체의 시장 규모(환자 수, 치료제 판매량) 동향 전망(종류별, 중증도별, 치료 종류별, 치료 계획별), 지역별 상세 동향, 주요 시장 촉진·억제요인, 주요 기업 개요 등을 조사하여 전해드립니다.

제1장 시장 개요

  • 혈우병이란?
  • 혈우병의 종류
  • 징후·증상
  • 혈우병의 진단 방법
  • 혈우병의 치료 방법

제2장 세계 시장 분석

  • 시장 규모(금액 기반)
  • 시장 규모 예측(금액 기반)
  • 시장 규모 : 레지멘(Regimen)별
  • 시장 규모 : 종류별
    • 혈우병 A 시장 예측(금액 기반)
    • 혈우병 A 시장 : 중증도별
    • 혈우병 A 시장 : 치료 종류별(예방/대처 요법)
    • 혈우병 A 시장 : 레지멘별
    • 혈우병 B 시장 예측(금액 기반)
    • 혈우병 B 시장 : 중증도별
    • 혈우병 B 시장 : 치료 종류별
    • 혈우병 B 시장 : 레지멘별

제3장 지역 시장 분석

  • 미국
    • 시장 규모(금액 기반)
    • 시장 규모 예측(금액 기반)
    • 시장 규모 : 종류별(금액 기반)
    • 시장 규모 예측 : 종류별(금액 기반)
    • 혈우병 A 시장 - 치료 환자 수 예측
    • 혈우병 A 시장 - 예방치료중인 중증 환자 수
    • 혈우병 A 시장 - 대처요법중인 중증 환자 수
    • 혈우병 A 시장 - 예방치료중인 경증·중증 환자 수
    • 혈우병 A 시장 - 대처요법중인 경증·중증 환자 수
    • 혈우병 B 시장 - 치료 환자 수 예측
    • 혈우병 B 시장 - 예방치료중인 중증 환자 수
    • 혈우병 B 시장 - 대처요법중인 중증 환자 수
    • 혈우병 B 시장 - 예방치료중인 경증·중증 환자 수
    • 혈우병 B 시장 - 대처요법중인 경증·중증 환자 수
  • 유럽
    • 혈우병 시장 : 환자 수 예측
    • 혈우병 A 시장 : 환자 수 예측
    • 혈우병 B 시장 : 환자 수 예측

제4장 시장 역학

  • 성장 촉진요인
  • 시장의 주요 동향과 기회
  • 과제

제5장 경쟁 환경

  • 세계 시장
    • 혈우병 A : 기업별 시장 점유율
    • 혈우병 A용 제VIII 인자 : 제품별 시장 점유율
    • 혈우병 A용 제VIII 인자 유전자 치료 : 시장 점유율, 예측
    • 혈우병 B : 기업별 시장 점유율
    • 혈우병 B용 제IX 인자 : 제품별 시장 점유율, 예측
    • 혈우병 B용 제IX 인자 유전자 치료 : 시장 점유율, 예측
  • 미국 시장
    • 혈우병 A 시장 : 기업별 시장 점유율
  • 유럽 시장
    • 혈우병 A 시장 : 기업별 시장 점유율

제6장 기업 개요

  • Pfizer Inc.
    • 사업 개요
    • 주요 재무 지표
    • 사업 전략
  • Bayer Group
  • Sanofi S.A.
  • Takeda Pharmaceutical Company
  • Novo Nordisk
  • CSL Limited
KSA 19.07.11

The global hemophilia market is estimated to reach US$12.98 billion in 2023, holding a CAGR of 6.21% in the duration spanning 2018-2023. The factors such as rise in diagnoses rate of hemophilia, rise in global healthcare expenditure and shifting focus to extended half-life (EHL) therapies are expected to drive the growth of the global hemophilia market. However, growth of the industry will be challenged by high price of treatment and reluctance to switch to new therapies. A few notable trends include shifting focus to Extended Half Life (EHL) therapies, development of novel hemophilia treatments and popularity of gene therapy.

The global hemophilia market comprises of two major segments: hemophilia A and hemophilia B. hemophilia A is four time prevalent than hemophilia B. The growing incidences of hemophilia A at vast rate has driven the increased demand for anti-hemophilia A or clotting factor VIII drugs. The pharmaceutical industry is flooded with drugs to be used in the treatment of type A, and thereby providing scope for the expansion of the global hemophilia market.

The fastest growing regional market in the hemophilia space is the U.S. due to High prevalence of hemophilia, coupled with rising inclination toward prophylaxis treatment. Rise in the population of hemophilia patients, is augmenting the need for more significant treatment methods. A lot of anti-hemophilia products are available in the market and several drugs are still in their late stage clinical process by large pharmaceutical firms. Furthermore, The U.S. and Europe are the highly established premium markets that contribute to considerable shares in the global hemophilia market.

Scope of the report:

The report provides a comprehensive analysis of the global hemophilia market, segmented into hemophilia A and hemophilia B.

The major regional markets (the U.S. and Europe) have been analyzed.

The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.

The competitive landscape of the market, along with the company profiles of leading players (Pfizer Inc., Bayer Group, Sanofi S.A., Takeda Pharmaceutical Company, Novo Nordisk and CSL Limited) are also presented in detail.

Key Target Audience:

  • Hemophilia Drugs Manufacturers
  • Raw Material Suppliers
  • End Users (Hospital, Medical centers, Clinical Institutes)
  • Healthcare Consulting Firms
  • Investment Banks
  • Government Bodies & Regulating Authorities

Table of Contents

1. Market Overview

  • 1.1 Hemophilia
  • 1.2 Types of Hemophilia
  • 1.3 Signs & Symptoms
  • 1.4 Diagnosis of Hemophilia
  • 1.5 Treatment of Hemophilia

2. Global Market Analysis

  • 2.1 Global Hemophilia Market by Value
  • 2.2 Global Hemophilia Market Forecast by Value
  • 2.3 Global Hemophilia Market by Treatment Regimen
  • 2.4 Global Hemophilia Market by Type
    • 2.4.1 Global Hemophilia A Market Forecast by Value
    • 2.4.2 Global Hemophilia A Market by Severity
    • 2.4.3 Global Hemophilia A Market by Treatment Type
    • 2.4.4 Global Hemophilia A Market by Treatment Regimen
    • 2.4.5 Global Hemophilia B Market Forecast by Value
    • 2.4.6 Global Hemophilia B Market by Severity
    • 2.4.7 Global Hemophilia B Market by Treatment Type
    • 2.4.8 Global Hemophilia B Market by Treatment Regimen

3. Regional Market Analysis

  • 3.1 The U.S.
    • 3.1.1 The U.S. Hemophilia Market by Value
    • 3.1.2 The U.S. Hemophilia Market Forecast by Value
    • 3.1.3 The U.S. Hemophilia Market by Type
    • 3.1.4 The U.S. Hemophilia A Market Forecast by Value
    • 3.1.5 The US Hemophilia A Market-Treated Patient Volume Forecast
    • 3.1.6 The US Hemophilia A Market-Severe Patients on Prophylactic Therapy
    • 3.1.7 The US Hemophilia A Market-Severe Patients on On-Demand Therapy
    • 3.1.8 The US Hemophilia A Market-Mild to Moderate Patients on Prophylaxis Therapy
    • 3.1.9 The US Hemophilia A Market-Mild to Moderate Patients on On-Demand Therapy
    • 3.1.10 The US Hemophilia B Market Forecast by Value
    • 3.1.11 The US Hemophilia B Market- Treated Patients Volume Forecast
    • 3.1.12 The US Hemophilia B Market- Severe Patients on Prophylaxis Therapy
    • 3.1.13 The US Hemophilia B Market- Severe Patients on On-Demand Therapy
    • 3.1.14 The US Hemophilia B Market- Mild to Moderate Patients on Prophylaxis Therapy
    • 3.1.15 The US Hemophilia B Market- Mild to Moderate Patients on On-Demand Therapy
  • 3.2 Europe
    • 3.2.1 Europe's Hemophilia Market- Patient Volume Forecast
    • 3.2.2 Europe's Hemophilia A Market- Patient Volume Forecast
    • 3.2.3 Europe's Hemophilia B Market- Patient Volume Forecast

4. Market Dynamics

  • 4.1 Growth Drivers
    • 4.1.1 Increased Focus on Prophylactic Treatment
    • 4.1.2 Increasing Diagnosis Rate
    • 4.1.3 Rise in Global Healthcare Expenditure
  • 4.2 Key Trends & Development
    • 4.2.1 Shifting Focus to Extended Half Life Therapies
    • 4.2.2 Development of Novel Hemophilia Treatments
    • 4.2.3 Popularity of Gene Therapy
  • 4.3 Challenges
    • 4.3.1 High Cost of Treatment
    • 4.3.2 Reluctance to Switch to New Therapies

5. Competitive Landscape

  • 5.1 The Global Market
    • 5.1.1 Global Hemophilia A Market Share by Company
    • 5.1.2 Global Hemophilia A Factor VIII Products Market Share by Company
    • 5.1.3 Global Hemophilia A FVIII Gene Therapy Market Share Forecast
    • 5.1.4 Global Hemophilia B Market Share by Company
    • 5.1.5 Global Hemophilia B Factor IX Products Market Share Forecast
    • 5.1.6 Global Hemophilia B Factor IX Gene Therapy Market Share Forecast
    • 5.1.7 Key Players - Main Anti-Hemophilia Products
    • 5.1.8 Key Players - Revenue Comparison
    • 5.1.9 Key Players - Market Capital Comparison
  • 5.2 The U.S. Market
  • The U.S. Hemophilia A Market Share by Company
  • 5.3 Europe Market
  • Europe Hemophilia A Market Share by Company

6. Company Profiles

  • 6.1 Pfizer Inc.
    • 6.1.1 Business Overview
    • 6.1.2 Financial Overview
    • 6.1.3 Business Strategies
  • 6.2 Bayer Group
    • 6.2.1 Business Overview
    • 6.2.2 Financial Overview
    • 6.2.3 Business Strategies
  • 6.3 Sanofi S.A.
    • 6.3.1 Business Overview
    • 6.3.2 Financial Overview
    • 6.3.3 Business Strategies
  • 6.4 Takeda Pharmaceutical Company
    • 6.4.1 Business Overview
    • 6.4.2 Financial Overview
    • 6.4.3 Business Strategies
  • 6.5 Novo Nordisk
    • 6.5.1 Business Overview
    • 6.5.2 Financial Overview
    • 6.5.3 Business Strategies
  • 6.6 CSL Limited
    • 6.6.1 Business Overview
    • 6.6.2 Financial Overview
    • 6.6.3 Business Strategies

List of Figures

  • Types of Hemophilia
  • Diagnosis of Hemophilia
  • Global Hemophilia Market by Value (2014-2018)
  • Global Hemophilia Market Forecast by Value (2019-2023)
  • Global Hemophilia Market by Treatment Regimen (2018)
  • Global Hemophilia Market by Type (2018)
  • Global Hemophilia A Market Forecast by Value (2018-2023)
  • Global Hemophilia A Market by Severity (2018)
  • Global Hemophilia A Market by Treatment Type (2018)
  • Global Hemophilia A Market by Treatment Regimen (2018/2023)
  • Global Hemophilia B Market Forecast by Value (2018-2023)
  • Global Hemophilia B Market by Severity (2018)
  • Global Hemophilia B Market by Treatment Type (2019)
  • Global Hemophilia B Market by Treatment Regimen (2018/2023)
  • The U.S. Hemophilia Market by Value (2014-2018)
  • The U.S. Hemophilia Market Forecast by Value (2019-2023)
  • The U.S. Hemophilia Market by Type (2018)
  • The U.S. Hemophilia A Market Forecast by Value (2018-2023)
  • The U.S. Hemophilia A Market-Treated Patient Volume Forecast (2018-2023)
  • The U.S. Hemophilia A Market-Severe Patients on Prophylactic Therapy (2018-2023)
  • The U.S. Hemophilia A Market-Severe Patients on On-Demand Therapy (2018-2023)
  • The U.S. Hemophilia A Market-Mild to Moderate Patients on Prophylaxis Therapy (2018-2023)
  • The U.S. Hemophilia A Market-Mild to Moderate Patients on On-Demand Therapy (2018-2023)
  • The U.S. Hemophilia B Market Forecast by Value (2018-2023)
  • The U.S. Hemophilia B Market- Treated Patients Volume Forecast (2018-2023)
  • The U.S. Hemophilia B Market- Severe Patients on Prophylaxis Therapy (2018-2023)
  • The U.S. Hemophilia B Market- Severe Patients on On-Demand Therapy (2018-2023)
  • The U.S. Hemophilia B Market- Mild to Moderate Patients on Prophylaxis Therapy (2018-2023)
  • The U.S. Hemophilia B Market- Mild to Moderate Patients on On-Demand Therapy (2018-2023)
  • Europe's Hemophilia Market- Patient Volume Forecast (2018-2023)
  • Europe's Hemophilia A Market- Patient Volume Forecast (2018-2023)
  • Europe's Hemophilia B Market- Patient Volume Forecast (2018-2023)
  • Global Market Share of Hemophilia A and B Patients on Prophylaxis (2018)
  • Global Identified Hemophilia Patients Volume (2011-2018)
  • Global Healthcare Expenditure (2014-2018)
  • Global Hemophilia A Market Share by Company (2017)
  • Global Hemophilia A Factor VIII Products Market Share by Company (2023/2030)
  • Global Hemophilia A FVIII Gene Therapy Market Share Forecast (2030)
  • Global Hemophilia B Market Share by Company (2017)
  • Global Hemophilia B Factor IX Products Market Share Forecast (2022/2030)
  • Global Hemophilia B Factor IX Gene Therapy Market Share Forecast (2030)
  • The US Hemophilia A Market Share by Company (2018)
  • Europe Hemophilia B Market Share by Company (2018)
  • Pfizer Inc. Revenue Share by Major Business Segment (2018)
  • Pfizer Inc. Revenue and Net Income (2014-2018)
  • Pfizer Inc. R&D Expenses (2016-2018)
  • Bayer Group Net Sales Share by Business Segments (2018)
  • Bayer Group Net Sales and Net Income (2014-2018)
  • Bayer Group R&D Expenses (2016-2018)
  • Sanofi S.A. Revenue Share by Segments (2018)
  • Sanofi S.A. Net Sales and Net Income (2014-2018)
  • Sanofi S.A. R&D Expenses (2016-2018)
  • Takeda Pharmaceutical Company Revenue Share by Region (2019)
  • Takeda Pharmaceutical Company Revenue and Net Income (2015-2019)
  • Takeda Pharmaceutical Company R&D Expenses (2017-2019)
  • Novo Nordisk Net Sales Share by Business Segments (2018)
  • Novo Nordisk Net Sales and Net Profit (2014-2018)
  • Novo Nordisk R&D Expenses (2016-2018)
  • CSL Limited Revenue Share by Segments (2018)
  • CSL Limited Sales Revenue and Net Profit (2014-2019)
  • CSL Limited R&D Expenses (2016-2018)

List of Tables

  • Signs & Symptoms of Hemophilia
  • Extended Half Life Products (2018)
  • Development of New Novel Hemophilia Treatments (2018)
  • Hemophilia Gene Therapy Candidates (2018)
  • Key Players - Main Anti-Hemophilia Products
  • Key Players - Revenue Comparison (2018)
  • Key Players - Market Capital Comparison (2019)
  • Major Products Developed by Pfizer Inc. (2018)
  • Major Products Developed by Bayer Group (2018)
  • Novo Nordisk Product Pipeline (2018)
Back to Top
전화 문의
F A Q